Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro-Reference-Cited by-同舟云学术

Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro

Published:2021-06-06 Issue:1 Volume:36 Page:150-159
ISSN:0767-3981
Container-title:Fundamental & Clinical Pharmacology
language:en
Short-container-title:Fundamemntal Clinical Pharma

Author:

liu Qian¹²,Ou‐Yang Qiu‐Geng³,Lin Qian‐Meng⁴,Lu Xiang‐Ran³,Ma Ya‐Qing²,Li Ying‐Hui³,Xu Ren‐Ai⁵,Lin Dong‐dong³,Hu Guo‐Xin³^ORCID,Cai Jian‐Ping¹²

Affiliation:

1. Chinese Academy of Medical Sciences Peking Union Medical College Beijing China

2. The Key Laboratory of Geriatrics Beijing Institute of Geriatrics Beijing Hospital National Center of Gerontology National Health Commission Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing China

3. School of Pharmacy Wenzhou Medical University Wenzhou Zhejiang China

4. Department of Oncology NHC Key Laboratory of Cancer Proteomics XiangYa Hospital Central South University Changsha China

5. Department of Pharmacy The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China

Funder

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/fcp.12693

Reference35 articles.

1. Administration F.A.D.FDA drug safety communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin;2014.

2. Administration F.A.D.FDA drug safety communication: FDA warns that DPP‐4 inhibitors for type 2 diabetes may cause severe joint pain;2015.

3. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study

4. Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human

5. Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism;Toxicology and Applied Pharmacology;2024-05

2. Pharmacokinetic interaction of saxagliptin with andrographolide and their hypoglycemic effect in type 2 diabetes rats;Acta Poloniae Pharmaceutica - Drug Research;2023-10-23

3. Astragalus injection alters the pharmacokinetics of doxorubicin and affects the activity of CYP450 enzymes;2023-06-26

4. Machine-learning models utilizing CYP3A4*1G show improved prediction of hypoglycemic medication in Type 2 diabetes;Personalized Medicine;2022-11-16

5. Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report;Frontiers in Oncology;2022-01-31